** Shares of lab operator Quest Diagnostics DGX.N rise as much as 7% to an over three-year high of $166.39
** Co's Q4 adj EPS of $2.23 beats Wall Street estimates of $2.19 - data compiled by LSEG
** DGX's Q4 revenue of $2.62 bln is above estimates of $2.58 bln
** Co expects 2025 revenue between $10.70 and $10.85 bln, above estimates of $10.67 bln
** Shares of peer Labcorp LH.N up 4.8%
** DGX shares rose 9.4% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.